Skip to content
JCP
PCC
News
CME
About
Authors & Reviewers
Sign In
Subscribe
Search
Advanced Search
Sign in
Menu
JCP
PCC
News
CME
About
Authors & Reviewers
Sign In
Subscribe
Clinical Topics
View All
Addiction
Anxiety
Bipolar Disorder
Depression
Difficult to Treat Depression
Emerging Approaches in Schizophrenia
Neurology
OCD
Psychopharmacology
PTSD and Trauma
Tardive Dyskinesia
View All
Collections
View All
Academic Highlights
Auvelity: Information from Industry
Banner Alzheimer’s Institute
Clinical & Practical Psychopharmacology
Early Career Psychiatrists
Focus on Childhood and Adolescent Mental Health
Focus on Geriatric Psychiatry
Focus on Psychotherapy
Focus on Suicide
Focus on Psychosis
Focus on Women’s Mental Health
Rounds in the General Hospital
View All
Ahmed Naguy, MBBch, MSc
PCC
Case Report
Levetiracetam—Through a Psychiatric Prism
November 21, 2019
Levetiracetam is often prescribed by neurologists. This report sheds light on the psychiatric sequelae associated with levetiracetam while highlighting clinical correlates and management issues.
Ahmed Naguy
PCC
Letter to the Editor
Paroxetine: Into Oblivion? Well, Guess Not
April 18, 2019
While paroxetine may have lost favor with some, it still has therapeutic potential in the treatment of various disorders. In this letter to the editor, the author urges clinicians...
Ahmed Naguy
PCC
Brief Report
Eponymous Psychiatric Syndromes Revisited
February 22, 2018
Here, the author provides an anthology of psychiatric eponyms. Clinically, many of these described syndromes represent valid diagnostic constructs and may accommodate the atypical cases that defy the official...
Ahmed Naguy
PCC
Letter to the Editor
Paroxetine: Into Oblivion?
January 11, 2018
Paroxetine is an selective serotonin reuptake inhibitor approved by the FDA for adult depression, obsessive-compulsive disorder, anxiety disorders, and vasomotor changes of menopause. Nonetheless, its clinical use has recently...
Ahmed Naguy
PCC
Letter to the Editor
Duloxetine for Difficult-to-Treat ADHD
December 29, 2016
Stimulants are a first-line treatment modality in the ADHD pharmacotherapy guidelines; yet, many subjects in clinical trials show an inadequate response. Read the case of a 14-year-old boy with...
Ahmed Naguy
«
1
2
3